MicroRNA‑208a‑3p participates in coronary heart disease by regulating the growth of hVSMCs by targeting BTG1
Affiliations: Department of Cardiac Surgery, Shanxi Bethune Hospital, Taiyuan, Shanxi 030001, P.R. China, Department of Nephrology, Shanxi Bethune Hospital, Taiyuan, Shanxi 030001, P.R. China
- Published online on: November 23, 2021 https://doi.org/10.3892/etm.2021.10994
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Human vascular smooth muscle cells (hVSMCs) are crucial in the progression of coronary heart disease (CHD). The present study aimed to investigate the role of microRNA‑208a‑3p (miR‑208a‑3p) in hVSMCs. Reverse transcription quantitative‑PCR was performed to detect the levels of miR‑208a‑3p in the peripheral blood samples of patients with CHD and healthy volunteers. The results showed that miR‑208a‑3p was significantly upregulated in peripheral blood samples from patients with CHD compared with in healthy volunteers. Bioinformatics analysis and dual‑luciferase reporter assays indicated that B‑cell translocation gene 1 (BTG1) was a direct target gene of miR‑208a‑3p, and was downregulated in the peripheral blood samples of patients with CHD. Furthermore, this study also suggested that miR‑208a‑3p served an inhibitory role in the proliferation of hVSMCs, induced cell apoptosis, promoted the protein expression of Bax and reduced Bcl‑2 protein expression; however, these effects were reversed by BTG1 silencing. In addition, the role of the PI3K/AKT pathway in mediating hVSMC apoptosis was examined via western blot analysis. Results indicated that inhibition of miR‑208a‑3p decreased phosphorylated (p)‑AKT protein expression levels and the ratio of p‑AKT/AKT in hVSMCs; however, BTG1‑small interfering RNA abolished these effects. Taken together, these findings revealed that miR‑208a‑3p served a critical role in CHD development, regulating hVSMC function via targeting of BTG1, which was associated with the PI3K/AKT signaling pathway. Therefore, downregulated miR‑208a‑3p may serve as an ideal therapeutic target for CHD diagnosis and therapy.